Ikonisys Signs Contract and Initiates Research Activities With Politecnico Di Milano, a World Leading Public Scientific-technological University in the Field of Computer Science and Bioengineering
24 Mai 2022 - 6:00PM
Business Wire
Regulatory News:
Ikonisys SA (Paris:ALIKO) (Code ISIN: FR00140048X2 /
Mnémonique: ALIKO), a company specializing in the early and
accurate detection of cancer with a unique fully-automated solution
for medical diagnostic labs and the Department of Electronics,
Information and Bioengineering (DEIB) of Politecnico di
Milano (POLIMI), a world-class scientific institution engaged
in cutting-edge research, training and technology transfer,
announced the signing of a research contract and the initiation of
a project to bear on the challenging problem of identifying
specific cells in complex tissues through designing, training and
deployment of a deep learning model able to detect them.
POLIMI is a world leader in computer science and bioengineering
and recently ranked 1st in Italy and 13th in the world for
Engineering in the QS World University Rankings by Subject
2022.
Prof. Giacomo Boracchi of the DEIB will lead the research
bringing his expertise in image processing and machine learning. In
particular, the approach will aim to recognize clinically relevant
cells of specific types in darkfield images of lung tissue acquired
from the Ikoniscope20. Segmentation of single cell nuclei is a
frequent challenge of microscopy image processing, often being the
first step of many quantitative data analysis pipelines.
The ongoing collaboration will allow Ikonisys to further enhance
its advanced image analysis capabilities and to accelerate the
development of the Ikoniscope AI project with the implementation of
deep learning models and novel state-of-art techniques into the
instrument’s workflow, leading to the development of new
applications or enhancement of the existing ones, especially in the
most challenging fields such as Circulating Tumor Cells.
Prof. Giacomo Boracchi, Politecnico di Milano DEIB,
commented, “We’re thrilled by the opportunity of working with
Ikonisys on a challenging subject like the detection of nuclei in
tissue specimens, which is well suited for our expertise in image
processing and machine learning. Systematic collaborations with the
industrial sector are of strategic importance for the DEIB and, as
demonstrated in several past projects, they often lead to impactful
industrial outcome. “
Dr Michael Kilpatrick, Chief Scientific Officer of
Ikonisys, added, “We are excited to be working with a world
class institution such as the DEIB at Politecnico di Milano. The
ability to utilize their cutting-edge expertise in AI and machine
learning to develop new methods for the identification and analysis
of clinically relevant cells offers an opportunity for Ikonisys to
continue to improve our image analysis proficiency. This will both
enhance the capabilities of the Ikoniscope20 for fully-automated
diagnostic analysis and expand the product portfolio of the company
by increasing the number and detail of the tissues for which
applications can be developed. “
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris
(France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The
company develops, produces and markets the proprietary
Ikoniscope20® platform, a fully-automated solution designed to
deliver accurate and reliable detection and analysis of rare and
very rare cells. Ikonisys has received FDA clearance for several
automated diagnostic applications, which are also marketed in
Europe under CE certification. Through its breakthrough
fluorescence microscopy platform, the company continues to develop
a stream of new tests, including liquid biopsy tests based on
Circulating Tumor Cells (CTC).
For further information, please go to www.Ikonisys.com
About Politecnico di Milano
Politecnico di Milano is a public scientific-technological
university which trains engineers, architects and industrial
designers. The University has always focused on the quality and
innovation of its teaching and research, developing a fruitful
relationship with business and productive world by means of
experimental research and technological transfer. Research has
always been linked to didactics and it is a priority commitment
which has allowed Politecnico Milano to achieve high quality
results at an international level as to join the university to the
business world. Research constitutes a parallel path to that formed
by cooperation and alliances with the industrial system. Knowing
the world in which you are going to work is a vital requirement for
training students. By referring back to the needs of the industrial
world and public administration, research is facilitated in
following new paths and dealing with the need for constant and
rapid innovation. The alliance with the industrial world, in many
cases favored by Fondazione Politecnico and by consortiums to which
Politecnico belong, allows the university to follow the vocation of
the territories in which it operates and to be a stimulus for their
development.
About DEIB
The Dipartimento di Elettronica, Informazione e Bioingegneria
(DEIB) aims at being a world-class scientific institution committed
to forefront research, education, and technology transfer in
computer science and engineering, electronics, electrical
engineering, systems and control, telecommunications, and
bioengineering.
The DEIB vision is to promote the quality and the impact of
Information and Communication Technology (ICT) on society at the
national and international level, by pursuing excellent long-term
and interdisciplinary research and by committing to innovation,
technology transfer, and education. While it is not easy to predict
the future use of information, the next decade will certainly see
even more dramatic changes, as ICT will find new ways of pervading
people’s lives. In this scenario, the DEIB is grounded on four
solid pillars:
- a tradition of excellence in fundamental research, with a clear
vision of its role and mission in “inventing the future”;
- an increasing engagement into interdisciplinary research, as
required by the ubiquitous presence of information technology into
every scientific and technological domain;
- a commitment to teaching in the challenging context of a
rapidly evolving discipline, by balancing stable foundational
principles with tumultuous changes in models, languages,
technologies, and standards;
- a commitment to applied research and to technology and
knowledge transfer, through joint research projects with local and
international industry and through many spin-off activities.
Disclaimer
This press release contains forward-looking statements about the
Company's prospects and development. These statements are sometimes
identified by the use of the future tense, the conditional tense
and forward-looking words such as "believe", "aim to", "expect",
"intend", "estimate", "believe", "should", "could", "would" or
"will" or, where appropriate, the negative of these terms or any
other similar variants or expressions. This information is not
historical data and should not be construed as a guarantee that the
facts and data set forth will occur. This information is based on
data, assumptions and estimates considered reasonable by the
Company. It is subject to change or modification due to
uncertainties relating to the economic, financial, competitive and
regulatory environment. This information contains data relating to
the Company's intentions, estimates and objectives concerning, in
particular, the market, strategy, growth, results, financial
situation and cash flow of the Company. The forward-looking
information contained in this press release is made only as of the
date of this press release. The Company does not undertake to
update any forward-looking information contained in this press
release, except as required by applicable law or regulation. The
Company operates in a competitive and rapidly changing environment
and therefore cannot anticipate all of the risks, uncertainties or
other factors that may affect its business, their potential impact
on its business or the extent to which the materialization of any
one risk or combination of risks could cause results to differ
materially from those expressed in any forward-looking information,
it being recalled that none of this forward-looking information
constitutes a guarantee of actual results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220524005935/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Olivier Bricaud / Louis-Victor Delouvrier Investor
Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 92
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024